Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
The triple-agonist injection also led nearly half of high-dose patients to lose 30% or more of their body weight, Lilly said.
- On Thursday, May 21, 2026, Eli Lilly announced that its investigational obesity treatment retatrutide cleared a Phase 3 clinical trial, with participants achieving up to 30.3% weight loss over 104 weeks.
- Dubbed the 'triple G' drug, retatrutide targets GLP-1, GIP, and glucagon hormone pathways, which Lilly said appears more potent than existing treatments at regulating appetite and metabolism.
- Yale School of Medicine Professor Ania Jastreboff, the study's lead investigator, called the results 'incredible,' noting participants on the highest dose lost an average of 70.3 lbs over 80 weeks.
- Results are on par with bariatric surgery, according to Lilly, though around 42% of patients on the highest dose experienced nausea, a common gastrointestinal side effect.
- Lilly plans to file for regulatory approval as early as this year, positioning retatrutide as a potential tool for patients who do not respond to current GLP-1 therapies.
35 Articles
35 Articles
A next-generation drug causes dramatic weight loss. Here’s how much.
Eli Lilly said on Thursday its experimental obesity drug helped patients lose more than 28 per cent of their weight over a year and a half in a key trial that allows the company to seek regulatory approval and potentially launch the next-generation drug next year.
New obesity drug helped patients lose up to 85 pounds in trial
A new experimental obesity drug from Eli Lilly helped patients lose an average of about 85 pounds in a late-stage clinical trial. Duke Health expert Dr. Susan Spratt says the results are reaching levels typically only seen with gastric bypass surgery.
A new weight loss drug shows dramatic results. Here’s how much better it performs vs. Ozempic
Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28 per cent of their weight over a year and a half in a key trial that helps pave the way for the firm to seek regulatory approval and launch the drug next year.
UPDATE 1-Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
In previous trials, it has been shown to boost weight loss well beyond Lilly's and its Danish rival's other drugs. In this late-stage trial for adults with obesity or who were overweight and at least one weight-related comorbidity, the firm found patients on the highest dose, 12 milligrams, of retatrutide lost an average of 28.3% of their weight over 80 weeks.
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Eli Lilly said on Thursday its experimental obesity drug helped patients lose more than 28% of their weight over a year and a half in a key trial that allows the company to seek regulatory approval and potentially launch the next-generation drug next year.
Coverage Details
Bias Distribution
- 52% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
